|
|
3. Last results presented in the World Menopause Congress
in May 2008
|
|
|
|
PHYTO SOYA® is the only soya isoflavones extract that has proved its safety after one year of treatment in a study performed using a methodology conforming to European recommendations.
This study was performed using the well-defined soya isoflavones formulation specifically represented by PHYTO SOYA®. Indeed, PHYTO SOYA® is extracted from the soya hypocotyl, in the heart of the bean. This study cannot, therefore, be extrapolated to other extracts with a different formulation.
|
|
|
|
|
|
Last results of an extensive clinical study have been presented in the World Menopause Congress in Madrid the 22nd of May 2008. This trial was an initiative of Arkopharma Laboratories and was conducted in Europe and Australia on more than 300 menopausal women between 45 and 65 years of age. For one year, they took two doses of Phyto Soya per day, one in the morning and one in the evening, for a total of 70 mg of isoflavones per day. This dosage corresponds to that of Extra-Strength Phyto Soya. Many women have decided to continue this clinical study for a total duration of 3 years, and some results can already be presented.
-
Phyto Soya® activity on Quality of life:
The results demonstrate Phyto Soya’s efficacy : after one year of use, the results showed that taking Phyto Soya had decreased number and intensity of hot flushes, night sweats and anxiety of menopausal women.
These results suggest that daily administration of 70 mg of Phyto Soya for 1 year improves the quality of life of menopausal women.
-
Phyto Soya® safe for Breast :
The results demonstrate Phyto Soya’s safety: after one year of use, the results showed that taking Phyto Soya had not changed mammary density. No precursory signs of cancer were observed. These results suggest that daily administration of 70 mg of Phyto Soya for 1 year is safe for the breast. Results after 3 years of use will be available very soon.
-
Phyto Soya® safe for Endometrium :
The results demonstrate Phyto Soya’s safety : after one year of use on more than 300 women, and after 3 years of use on 87 women, no suspicious or cancerous lesions were detected. No increase in the thickness of the endometrium was observed (no cases of endometrial hyperplasia were reported). These results suggest that daily administration of 70 mg of Phyto Soya for 1 year does not stimulate the endometrium and is safe in use.
-
Accede the slides of presentations showed during the world congress of menopause (Arkpoharma symposium) :
1- Endometrial safety assessment of a specific and standardized soy extract Pr. Santiago Palacios
2- Mammographic breast density evaluation after one year soy extract treatment Dr. Bruno Pornel
3- Quality of life of post menopausal women treated for 1 year with a soy extract Pr. Pierre Marès
|
|
|
Phyto Soya International Symposium 2008 - Introduction
Phyto Soya International Symposium 2008 - Pr. Santigo Palacios
Phyto Soya International Symposium 2008 - Dr. Bruno Pornel
Phyto Soya International Symposium 2008 - Pr. Pierre Marès
|
|
|
